6th Dermatology Drug Development Summit 2022

Welcome to the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases

The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. Amidst the immense range and a steady stream of the novel, topical, and systemic agents entering exciting early phases, now is the time to gain insight from other leaders in the space.

As the world's leading and only forum committed to overcoming significant R&D hurdles and sharing best practices for advancing efficacious next-generation therapies for chronic inflammatory skin conditions, can you really afford to miss out?

With the rising demand for patient-specific and alternative treatment options, along with some first-in-class treatments in the likes of Alopecia Areata – the 6th annual meeting addresses genetic discoveries, antibody drug development, delivery strategies, and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.

Ensure you join    this year's 150+ expert community in-person to:
. Uncover recent studies evaluating critical inflammatory and auto-immune pathways
. Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases.
. Assess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways
. Obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as 
Hidradenitis Suppurativa, Vitiligo, Rare Disease, and Alopecia Areata

Speakers: Christopher Bunick, Associate Professor Dermatology, Yale School of Medicine, John Harris, Professor and Chair, Department of Dermatology Founding Director, Vitiligo Clinic and Research Center Founding Director, Autoimmune Therapeutics Institute, Paul Smith, Vice President Discovery Biology, Connect Biopharma, Steve Connelly, Co-founder and Chief Scientific Officer, Equillium Bio, Annie Zhang, Global Medical Director Immunology and Dermatology, Sanofi, Jennifer Good, Chief Executive Officer, Trevi Therapeutics, Laurence Cheng, Vice President Clinical Development, RAPT Therapeutics, Andre Boulet, President and Chief Executive Officer, Devonian, Arash Mostaghimi, Assistant Professor, Director of Inpatient Dermatology Consult Service, Brigham and Women's Hospital, Kim Kjoller, Chief Executive Officer, UNION Therapeutics, Alan Mendelsohn, Chief Medical Officer, Timber Pharmaceuticals, Bridget Cole Senior, Vice President Drug Discovery, Nocion Therapeutics, Bruce Randazzo, Vice President Clinical Development, AnaptysBio, Humberto Antunes, Partner/Former Chief Executive Officer, Gore Range Capital/Galderma, John M. Armstrong PHD, Managing Director, Outcome Capital, Ricardo Rojo, Cellas Global Clinical Lead, Janssen, Chidi Nwankpa, Healthcare and Life Science Investor, Gore Range Capital, Miles Nunn, Chief Scientific Officer, Akari Therapeutics, Rachelle Jacques, Chief Executive Officer, Akari Therapeutics, Benjamin Ungar, Director of Rosacea and Seborrheic Dermatitis Clinic, Mount Sinai, Nicholas Gulati, Assistant Professor Dermatology, Director Oncodermatology Clinic, Mount Sinai, Primal Kaur, Vice President Global Development, Amgen, Angela Christiano, Professor Dermatology and Genetics, Columbia University, John Koconis, Chief Executive Officer, Timber Pharmaceuticals, Suma Krishnan, Chief Executive Officer, Krystal Biotech, Alexandra Charrow, Director Hidradenitis Suppurativa and Neutrophilic Dermatosis Clinic, Brigham and Women's Hospital, Joyce Teng, Professor of Dermatology, Stanford University, Monica Luchi, Chief Medical Officer, Brickell Biotech, Kristian Reich, Founder and Chief Scientific Officer, MoonLake Immunotherapeutics, Mary Spellman, Chief Medical Officer, Castle Creek BioSciences, Thorsten Thormann, Vice President Head of Research and Early Development, LEO Pharma, Henrique Teixeira, Group Scientific Director Immunology Clinical Development, AbbVie, Jennifer Gaskin, Senior Director Clinical Operations, Celldex Therapeutics, John Reader, Chief Scientific Officer, Sareum, David Chu PhD, Executive Director Clinical Development, Arcutis Therapeutics, Jean-Louis Saillot, Chief Development Officer, Inmagene Biopharmaceuticals, Lotus Mallbris, Vice President, Clinical and Product Development and Medical Affairs, Eli Lilly and Co., Andy Blauvelt MD M.B.A, President, Oregon Medical Research Center, Patrick Brunner, Associate Professor, Icahn School of Medicine, Mount Sinai, Paul Klekotka, Senior Medical Director, Eli Lilly and Co, Dr. Signe Holm Nielsen, Scientific Lead Dermatology, Nordic Bioscience, Dr. Vijendra Nalamothu, Chairman and CEO, Tergus Pharma, Kumar Krishnaswamy, Head of Translational Medicine, Galderma, Dan Piacquadio, MD President and CEO, Therapeutics Inc, Harald Schnidar, CEO and Founder, SCARLETRED, Stefan C. Weiss, MD, MHSc, MBA Managing Director, Dermatology OM1

Others Details

Brochure: https://go.evvnt.com/1216917-2?pid=6581